GlaxoSmithKline LLC, et al. v. Glenmark Pharmaceuticals Inc., USA, et al., C.A. Nos. 14-877-LPS-CJB; 14-878-LPS-CJB, June 3, 2016.
Burke, M. J. Report and Recommendation regarding claim construction issues regarding six terms from one patent. A Markman hearing took place on April 4, 2016.
The disputed technology relates to a beta blocking pharmaceutical. The following terms were considered:
- “decreasing mortality caused by congestive heart failure" I "to decrease a risk of mortality caused by congestive heart failure"
- “maintenance period”
- “maintenance dosages”
- "have been shown to statistically decrease"
- "congestive heart failure"